News articles about Anavex Life Sciences (NASDAQ:AVXL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anavex Life Sciences earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.1814773504367 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research firms have recently commented on AVXL. Maxim Group set a $5.00 price target on Anavex Life Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 14th. ValuEngine lowered Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. Roth Capital began coverage on Anavex Life Sciences in a research report on Thursday, March 8th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences in a research report on Tuesday, December 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $7.63.

Shares of Anavex Life Sciences (NASDAQ:AVXL) traded up $0.05 during trading hours on Wednesday, reaching $2.80. The company had a trading volume of 223,160 shares, compared to its average volume of 311,435. Anavex Life Sciences has a 12 month low of $2.25 and a 12 month high of $6.49. The firm has a market cap of $122.58, a price-to-earnings ratio of -8.24 and a beta of 1.05.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. research analysts expect that Anavex Life Sciences will post -0.41 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Insider Buying and Selling by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with's FREE daily email newsletter.